We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 19, 2022

Addition of Orteronel to ADT for Patients With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)
J. Clin. Oncol 2022 Apr 21;[EPub Ahead of Print], N Agarwal, CM Tangen, MHA Hussain, S Gupta, M Plets, PN Lara, AL Harzstark, PW Twardowski, CJ Paller, D Zylla, MR Zibelman, E Levine, BJ Roth, A Goldkorn, DA Vaena, M Kohli, T Crispino, NJ Vogelzang, IM Thompson, DI Quinn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading